Business
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents
About this update from Fibrobiologics, Inc.
[{"type":"text","content":"HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells. The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cells. This includes cells such as T cells, B cells, NK cells, macrophages, monocytes, neutrophils, platelets, red blood cells, myeloid-derived suppressor cells, mast cells, eosinophils, basophils, dendritic cells, and CAR-T cells. “This method potentially offers a rapid, cost-effective, and scalable way to produce therapeutic hemopoietic organoids, which can be transplanted into a living organism to generate desired functional immune cells,” commented Chief Scientific Officer of FibroBiologics, Hamid Khoja, Ph.D. “Additionally, the three-dimensional organoids can be ready for immediate transplantation into a subject within three days of culture or cryopreserved for later use.” “Our ongoing exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our platform,” commented Founder & CEO of FibroBiologics, Pete O’Heeron. “This patent, if issued, will allow us to pursue the development of a versatile, scalable solution for generating immune cells in vivo that could revolutionize regenerative medicine and cancer immunotherapy.” For more information, please visit FibroBiologics' website or email FibroBiologics at [email protected]. Cautionary Statement Regarding Forward-Looking Statements This communication contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential to produce therapeutic hemopoietic organoids and to generate desired functional immune cells, the speed of transplantation, and FibroBiologics’ ability to pursue the development of a solution for generating immune cel...